Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Showkat Ahmad Mir & Binata Nayak. (2023) Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with T790M/L858R EGFR-TKD. Journal of Biomolecular Structure and Dynamics 41:8, pages 3702-3716.
Read now
Read now
Ibrahim Azar, Samer Alkassis, Jami Fukui, Fares Alsawah, Kalub Fedak, Mohammed Najeeb Al Hallak, Ammar Sukari & Misako Nagasaka. (2021) Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy 12, pages 103-114.
Read now
Read now
Corey A. Carter, Joel Anthony Nations & Angeline Lazarus. (2014) Molecular Targets in the Treatment of Non—Small-Cell Lung Cancer: Is There Hope on the Horizon?. Postgraduate Medicine 126:7, pages 139-148.
Read now
Read now
Carlo Genova, Erika Rijavec, Giulia Barletta, Giovanni Burrafato, Federica Biello, Maria Giovanna Dal Bello, Simona Coco, Anna Truini, Angela Alama, Francesco Boccardo & Francesco Grossi. (2014)
Afatinib for the treatment of advanced non-small-cell lung cancer. Expert Opinion on Pharmacotherapy 15:6, pages 889-903.
Read now
Read now
Articles from other publishers (47)
Ting Zou, Jun-Yan Liu, Qun Qin, Jie Guo, Wen-Zhi Zhou, Xiang-Ping Li, Hong-Hao Zhou, Juan Chen & Zhao-Qian Liu. (2023) Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Biomedicines 11:12, pages 3133.
Crossref
Crossref
Yuanyuan Zhang, Mingchen Zhu, Jianhua Zhu, Feifei Xu & Yun Chen. (2023) Nanoproteomics deciphers the prognostic value of EGFR family proteins-based liquid biopsy. Analytical Biochemistry 671, pages 115133.
Crossref
Crossref
Mohammadreza Lashkarizadeh, Mahdiyeh Lashkarizadeh, Meead Nikian & Maryam Kouhestani Parizi. (2023) The expression of HER2/neu in patients with lung cancer and its associated factors. The Clinical Respiratory Journal 17:2, pages 90-95.
Crossref
Crossref
Rahela Zaman, Rowshan Ara Islam & Ezharul Hoque Chowdhury. (2022) Evolving therapeutic proteins to precisely kill cancer cells. Journal of Controlled Release 351, pages 779-804.
Crossref
Crossref
Qing Wang, Xindi Zhang, Weijun Wei & Min Cao. (2022) PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective. Molecular Pharmaceutics 19:10, pages 3471-3483.
Crossref
Crossref
Long Chen, Fukun Chen, Jindan Li, Yongzhu Pu, Conghui Yang, Yue Wang, Yujie Lei & Yunchao Huang. (2022)
CAR‐T
cell therapy for lung cancer: Potential and perspective
. Thoracic Cancer 13:7, pages 889-899.
Crossref
Crossref
Xueli Tian, Tingxuan Gu, Mee-Hyun Lee & Zigang Dong. (2022) Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:1, pages 188645.
Crossref
Crossref
Shuyi Cen, Zhen Liu, Hongming Pan & Weidong Han. (2021) Clinicopathologic features and treatment advances in cancers with HER2 alterations. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:2, pages 188605.
Crossref
Crossref
D. A. Kharagezov, Yu. N. Lazutin, E. A. Mirzoyan, A. G. Milakin, O. N. Stateshny, I. A. Leiman, A. V. Chubaryan & K. D. Iozefi. (2021) Клинический случай легочной формы мукормикоза у ребенка с острым лимфобластным лейкозом. South Russian Journal of Cancer 2:4, pages 38-47.
Crossref
Crossref
Akihiro Miura, Daisuke Yamada, Masahiro Nakamura, Shuta Tomida, Dai Shimizu, Yan Jiang, Tomoka Takao, Hiromasa Yamamoto, Ken Suzawa, Kazuhiko Shien, Masaomi Yamane, Masakiyo Sakaguchi, Shinichi Toyooka & Takeshi Takarada. (2021)
Oncogenic potential of human pluripotent stem cell‐derived lung organoids with
HER2
overexpression
. International Journal of Cancer 149:8, pages 1593-1604.
Crossref
Crossref
Pamela Abdayem & David Planchard. (2021) Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. European Respiratory Review 30:161, pages 200294.
Crossref
Crossref
Devina Laishram, Vandana Raphael, Evarisalin Marbaniang, Caleb Harris, Vikas Jagtap & Baphiralyne Wankhar. (2021) Study of Programmed Death Ligand 1 and EGFR/HER2 Expression in Non-Small-Cell Lung Carcinoma With a Clinicopathological Spectrum. Cureus.
Crossref
Crossref
Paul Hofman. (2021) What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy. Journal of Molecular Pathology 2:2, pages 147-172.
Crossref
Crossref
Sara S. Fois, Panagiotis Paliogiannis, Angelo Zinellu, Alessandro G. Fois, Antonio Cossu & Giuseppe Palmieri. (2021) Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 22:2, pages 612.
Crossref
Crossref
Surya K. Tripathi, Kamal Pandey, Kannan R. R. Rengasamy & Bijesh K. Biswal. (2020) Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer. Medicinal Research Reviews 40:6, pages 2132-2176.
Crossref
Crossref
Sitanshu S. Singh, Achyut Dahal, Leeza Shrestha & Seetharama D. Jois. (2020) Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. Current Medicinal Chemistry 27:32, pages 5274-5316.
Crossref
Crossref
M. Jebbink, A.J. de Langen, M.C. Boelens, K. Monkhorst & E.F. Smit. (2020) The force of HER2 – A druggable target in NSCLC?. Cancer Treatment Reviews 86, pages 101996.
Crossref
Crossref
Dmitriy Minond. (2020) Novel Approaches and Challenges of Discovery of Exosite Modulators of a Disintegrin and Metalloprotease 10. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Karen L. Reckamp. (2020) Molecular Targets Beyond the Big 3. Thoracic Surgery Clinics 30:2, pages 157-164.
Crossref
Crossref
Amaia Eleonora Maennling, Mehmet Kemal Tur, Marcus Niebert, Torsten Klockenbring, Felix Zeppernick, Stefan Gattenlöhner, Ivo Meinhold-Heerlein & Ahmad Fawzi Hussain. (2019) Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers 11:12, pages 1826.
Crossref
Crossref
Kim, Jo, Jang, Nguyen, Yun, Ko, Shin, Lee, Kang, Ha, Choi & Kim. (2019) PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma. Cancers 11:11, pages 1749.
Crossref
Crossref
Qingqing Ding, Hui Chen, Bora Lim, Senthil Damodaran, Weiwei Chen, Debu Tripathy, Sarina Piha-Paul, Rajyalakshmi Luthra, Funda Meric-Bernstam & Aysegul A. Sahin. (2019) HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Human Pathology 92, pages 32-38.
Crossref
Crossref
Donatella Romaniello, Luigi Mazzeo, Maicol Mancini, Ilaria Marrocco, Ashish Noronha, Matthew Kreitman, Swati Srivastava, Soma Ghosh, Moshit Lindzen, Tomer Meir Salame, Amir Onn, Jair Bar & Yosef Yarden. (2018) A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Clinical Cancer Research 24:22, pages 5610-5621.
Crossref
Crossref
Rong Wang, Zhiqiang Yin, Lingxiang Liu, Wen Gao, Wei Li, Yongqian Shu & Jiali Xu. (2018) Second Primary Lung Cancer After Breast Cancer: A Population-Based Study of 6,269 Women. Frontiers in Oncology 8.
Crossref
Crossref
Cecilia Lopez Sambrooks, Marta Baro, Amanda Quijano, Azeet Narayan, Wei Cui, Patricia Greninger, Regina Egan, Abhijit Patel, Cyril H. Benes, W. Mark Saltzman & Joseph N. Contessa. (2018) Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research 78:17, pages 5094-5106.
Crossref
Crossref
Federico Cappuzzo & Lorenza Landi. (2018)
HER2
Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
. Clinical Cancer Research 24:11, pages 2470-2472.
Crossref
Crossref
Jing Xu, Jinghui Wang & Shucai Zhang. (2017) Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. Oncotarget 8:52, pages 90557-90578.
Crossref
Crossref
Aoli Wang, Xixiang Li, Hong Wu, Fengming Zou, Xiao-E Yan, Cheng Chen, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun, Jing Liu & Qingsong Liu. (2017)
Discovery of (
R
)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1
H
-pyrazolo[3,4-
d
]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode
. Journal of Medicinal Chemistry 60:7, pages 2944-2962.
Crossref
Crossref
A. K. M. Azad, Alfons Lawen & Jonathan M. Keith. (2017) Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer. PLOS ONE 12:3, pages e0173331.
Crossref
Crossref
Jing Jiang, Lihou Dong, Lei Wang, Ling Wang, Jing Zhang, Fang Chen, Xiuli Zhang, Min Huang, Shenjun Li, Weiwei Ma, Qiaoyu Xu, Changjiang Huang, Jianmin Fang & Chunhua Wang. (2016) HER2-targeted antibody drug conjugates for ovarian cancer therapy. European Journal of Pharmaceutical Sciences 93, pages 274-286.
Crossref
Crossref
Ning Zhao, Siyu Liu, Qike Jiang, Tian Lan, Zhen Cheng & Hongguang Liu. (2016) Small-Protein-Stabilized Semiconductor Nanoprobe for Targeted Imaging of Cancer Cells. ChemBioChem 17:13, pages 1202-1206.
Crossref
Crossref
Silvio De Flora, Gancho Ganchev, Marietta Iltcheva, Sebastiano La Maestra, Rosanna T. Micale, Vernon E. Steele & Roumen Balansky. (2016) Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence. Trends in Pharmacological Sciences 37:2, pages 120-142.
Crossref
Crossref
Eirik Sundby, Jin Han, Svein Jacob Kaspersen & Bård Helge Hoff. (2015) In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib. European Journal of Pharmaceutical Sciences 80, pages 56-65.
Crossref
Crossref
Maxime Guéguinou, Audrey Gambade, Romain Félix, Aurélie Chantôme, Yann Fourbon, Philippe Bougnoux, Günther Weber, Marie Potier-Cartereau & Christophe Vandier. (2015) Lipid rafts, KCa/ClCa/Ca2+ channel complexes and EGFR signaling: Novel targets to reduce tumor development by lipids?. Biochimica et Biophysica Acta (BBA) - Biomembranes 1848:10, pages 2603-2620.
Crossref
Crossref
Diego Marquez-Medina & Sanjay Popat. (2015) Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Future Oncology 11:18, pages 2525-2540.
Crossref
Crossref
Lihua Huang & Liwu Fu. (2015) Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B 5:5, pages 390-401.
Crossref
Crossref
Oksana Kowalczuk, Miroslaw Kozlowski, Robert Milewski, Lukasz Minarowski & Joanna Reszec. (2015) Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study. Advances in Medical Sciences 60:2, pages 277-286.
Crossref
Crossref
Julian Ananiev, Elina Aleksandrova, Desislava Skerleva, Maya Gulubova, Anastasiya Chokoeva, Torello Lotti, Uwe Wollina, Georgi Tchernev, Milica Kontić & Jelena Stojšić. (2015) Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patientsZur Bedeutung des HER2 Codon 655-Polymorphismus und der Expression von HER2 und HER3 bei Patienten mit einem nicht-kleinzelligen Lungenkarzinom. Wiener Medizinische Wochenschrift 165:15-16, pages 315-321.
Crossref
Crossref
M.G. Kris, D.R. Camidge, G. Giaccone, T. Hida, B.T. Li, J. O'Connell, I. Taylor, H. Zhang, M.E. Arcila, Z. Goldberg & P.A. Jänne. (2015) Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Annals of Oncology 26:7, pages 1421-1427.
Crossref
Crossref
Ling Shan, Tian Qiu, Yun Ling, Lei Guo, Bo Zheng, Bingning Wang, Wenbin Li, Lin Li & Jianming Ying. (2015) Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma. PLOS ONE 10:6, pages e0130447.
Crossref
Crossref
Hyo Sup Shim, Ja Seung Koo & Se Hoon Kim. 2015. Brain Metastases from Primary Tumors. Brain Metastases from Primary Tumors
69
75
.
Juliana Eng, Alexander Drilon & Paul K. Paik. 2015. Diagnosing Non-small Cell Carcinoma in Small Biopsy and Cytology. Diagnosing Non-small Cell Carcinoma in Small Biopsy and Cytology
129
154
.
Daniele Cretella, Francesca Saccani, Federico Quaini, Caterina Frati, Costanza Lagrasta, Mara Bonelli, Cristina Caffarra, Andrea Cavazzoni, Claudia Fumarola, Maricla Galetti, Silvia La Monica, Luca Ampollini, Marcello Tiseo, Andrea Ardizzoni, Pier Giorgio Petronini & Roberta R Alfieri. (2014) Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Molecular Cancer 13:1.
Crossref
Crossref
Roumen Balansky, Alberto Izzotti, Francesco D’Agostini, Mariagrazia Longobardi, Rosanna T. Micale, Sebastiano La Maestra, Anna Camoirano, Gancho Ganchev, Marietta Iltcheva, Vernon E. Steele & Silvio De Flora. (2014) Assay of lapatinib in murine models of cigarette smoke carcinogenesis. Carcinogenesis 35:10, pages 2300-2307.
Crossref
Crossref
Kevin E. Fisher, Rathi N. Pillai, Ragini R. Kudchadkar & Michael R. Rossi. (2014) Section IV: Non–small cell lung cancer and malignant melanoma. Current Problems in Cancer 38:5, pages 180-198.
Crossref
Crossref
Junya Fujimoto & Ignacio I. Wistuba. (2014) Current concepts on the molecular pathology of non-small cell lung carcinoma. Seminars in Diagnostic Pathology 31:4, pages 306-313.
Crossref
Crossref
Juliana Inês Santos, Ana Luísa Teixeira, Francisca Dias, Mónica Gomes, Augusto Nogueira, Joana Assis & Rui Medeiros. (2014) Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development. Tumor Biology 35:7, pages 6245-6253.
Crossref
Crossref